46th week of 2013 patent applcation highlights part 52 |
Patent application number | Title | Published |
20130303405 | METHOD FOR MANUFACTURING AN ANALYSIS SUBSTRATE, AND USE THEREOF FOR DETECTING TOXINS - The présent invention relates to a method for manufacturing an analysis device including torpédo membrane fragments immobilized at the surface thereof, to the resulting analysis device, and to the use of said device for detecting, purifying, and characterizing molécules acting on nicotinic acetylcholine receptors. The présent invention is useful in the field of monitoring seafood, monitoring neurotoxic phytoplankton for the shellfish industry, monitoring the quality of bathing waters along tourist beaches, the field of monitoring fresh water reserves, the field of médical research, the field of the biological analysis and characterization of molécules, e.g., non-radioactive assays of the movement of the ligand-receptor bond on an ELISA-type microplate, thereby enabling compétitive agonists and antagonists of targets to be detected, e.g., of highly sensitive receptors. | 2013-11-14 |
20130303406 | ENGINEERING OF IMMUNOGLOBULIN DOMAINS - The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a V | 2013-11-14 |
20130303407 | COMPOSITIONS AND METHODS FOR PROCESSING AND AMPLIFICATION OF DNA, INCLUDING USING MULTIPLE ENZYMES IN A SINGLE REACTION - The present invention concerns preparation of DNA molecules, such as a library, using a stem-loop oligonucleotide. In particular embodiments, the invention employs a single reaction mixture and conditions. In particular, at least part of the inverted palindrome is removed during the preparation of the molecules to facilitate amplification of the molecules. Thus, in specific embodiments, the DNA molecules are suitable for amplification and are not hindered by the presence of the palindrome. | 2013-11-14 |
20130303408 | ASSEMBLIES FOR MULTIPLEX BINDING ASSAYS - Assay plate assemblies are disclosed. The assemblies include an assay plate that has a top side, a bottom side, and at least one well accessible from the top side of the plate. The well includes a side surface and a bottom surface, with at least one secondary container protruding through the bottom surface and into an interior volume of the well. The assemblies further include a dispenser plate that is adapted to be positioned adjacent to the top side of the assay plate. The dispenser is further configured to provide one or more reagents to one or more secondary containers of at least one well of the assay plate. | 2013-11-14 |
20130303409 | AUTOMATICALLY CONTROLLING A PLURALITY OF DEVICES OF A SEPARATION AND DETECTION PROCESS FOR QUANTITATIVE SAMPLE ANALYSIS - A control system ( | 2013-11-14 |
20130303410 | Invert Emulsion Drilling Fluids for Flat Rheology Drilling - An invert emulsion drilling fluid, and a method of drilling with such fluid, having substantially flat or relatively controlled rheology, as demonstrated by the drilling fluid exhibiting little change in its yield point and gel strength across a temperature range of from about 40° F. to about 180° F., and effected with addition of a fatty dimer diamine additive together with an acid and without the addition of organophilic clays or lignites. | 2013-11-14 |
20130303411 | Methods and Materials to Enhance High Temperature Rheology in Invert Emulsions - An invert emulsion drilling fluid, and a method of drilling with such fluid, having improved rheology at low mud weights and high temperatures. The improved rheology is effected with addition of a rheology additive of the invention comprising fatty dimer diamines or dimer diamines and an organic acid or ester of the acid. A nonlimiting example of such a rheology additive comprises a C36 fatty dimer diamine and adipic acid or dimethyl adipate. | 2013-11-14 |
20130303412 | Viscosified Fluid Loss Control Agent Utilizing Chelates - Disclosed herein is a well treatment method comprising the steps of injecting into a well a fluid loss control agent comprising a chelating agent, a viscosity increasing agent, and a plurality of at least partially insoluble bridging solid particles dispersed therein, wherein the chelating agent is effective to at least partially solubilize at least a portion of the bridging solid particles over a solubilizing period of time for thereafter substantially dissolving the bridging solid particles, wherein the solubilizing period of time is controlled by the concentration of the viscosity increasing agent, the concentration of the chelating agent, the composition of the metal salt, the pH of the fluid loss control agent, or a combination thereof. A fluid loss control agent is also disclosed. | 2013-11-14 |
20130303413 | WEAR RESISTANT ARTICLE - The disclosure generally relates to wear resistant articles such as a turbine fan blade, a rotor disk, etc. having a composited lubricated sheet adhered thereon and having improved tribological properties at high temperatures. | 2013-11-14 |
20130303414 | MOLYBDENUM MONOXIDE LAYERS, AND PRODUCTION THEREOF USING PVD - The invention relates to a coating comprising at least one molybdenum-containing layer having molybdenum oxide, said molybdenum being essentially molybdenum monoxide. The invention further relates to a PVD process for producing the disclosed coating, in which the layer comprising the molybdenum monoxide is produced using arc evaporation. The invention also relates to a component that has said coating. | 2013-11-14 |
20130303415 | Asphaltene Dispersant Containing Lubricating Compositions - The present invention relates to a lubricating composition, particularly marine diesel engine lubricating compositions, comprising: (a) an oil of lubricating viscosity; (b) an asphaltene dispersant comprising an amide group, which may also contain a succinimide group, and which may optionally be used in combination with additional asphaltene dispersants that contain a cyclic headgroup that contains a nitrogen atoms where the additional asphaltene dispersants may also include a succinimide group; and (c) a detergent derived from an alkyl phenol. The invention further provides methods of using such compositions in the operation of engine, particularly marine diesel engines. | 2013-11-14 |
20130303416 | MANNICH CONDENSATION PRODUCTS USEFUL AS SEQUESTERING AGENTS - The present invention is directed to Mannich condensation product sequestering agents or mixtures of Mannich condensation product sequestering agents for use in fuels and lubricating oils. The present invention is also directed to a process for preparing the Mannich condensation product sequestering agents. The present invention is also directed to a product formed by combining, under reaction conditions, a polyisobutyl-substituted hydroxyaromatic compound, an aldehyde, an amino acid or ester thereof, and an alkali metal base to form the Mannich condensation product sequestering agent. The present invention is also directed to a lubricating oil composition, a lubricating oil concentrate, a fuel composition, and a fuel concentrate having the Mannich condensation product sequestering agents of the present invention. | 2013-11-14 |
20130303417 | Lubricating Compositions Containing An Antiwear Agent - The invention provides a lubricating composition containing an oil of lubricating viscosity and a compound obtained/obtainable by a process comprising reacting a glycolic acid, a 2-halo-acetic acid, or a lactic acid, or an alkali or alkaline metal salts thereof, (typically glycolic acid or a 2-halo-acetic acid) with at least one member selected from the group consisting of an amine, an alcohol, and an aminoalcohol. The invention further relates to the use of the lubricating composition in an internal combustion engine. | 2013-11-14 |
20130303418 | HIGH MOLECULAR WEIGHT POLYMERS AS VISCOSITY MODIFIERS - A lubricating composition comprises a base oil and between 10 ppm and 1000 ppm by mass of a viscosity modifier, the viscosity modifier comprising a polymer having a number average molecular weight greater than 500,000. The polymer's side-chains may be branched or unbranched. The polymer is preferably selected from the group consisting of polyolefin, poly alpha olefin, poly internal olefin, ethylene-propylene copolymers, ethylene-propylene-diene copolymers, ethylene-propylene-acrylate copolymers, ethylene-propylene-methacrylate copolymers, ethylene-propylene-aromatic copolymers, ethylene-propylene-diene-acrylate copolymers, ethylene-propylene-diene-methacrylate copolymers, and combinations thereof. | 2013-11-14 |
20130303419 | PROCESS OF MAKING AN ARTICLE FOR DISSOLUTION UPON USE TO DELIVER SURFACTANTS - A process that results in a flexible dissolvable porous solid article that can be used as a personal care composition or a fabric care composition. | 2013-11-14 |
20130303420 | COMPOSITION FOR AND METHOD OF SUPPRESSING TITANIUM NITRIDE CORROSION - Cleaning compositions and processes for cleaning residue from a microelectronic device having said residue thereon. The composition comprises at least one amine, at least one oxidizing agent, water, and at least one borate species and achieves highly efficacious cleaning of the residue material, including post-ash residue, post-etch residue, post-CMP residue, particles, organic contaminants, metal ion contaminants, and combinations thereof from the microelectronic device while simultaneously not damaging the titanium nitride layers and low-k dielectric materials also present on the device. | 2013-11-14 |
20130303421 | PHOTORESIST STRIPPING TECHNIQUE - Photoresist stripping solutions are disclosed. An exemplary solution includes an organic solvent and an organic base, wherein the organic base is represented by the formula: | 2013-11-14 |
20130303422 | LABEL REMOVAL SOLUTION FOR RETURNABLE BEVERAGE BOTTLES - According to the invention, the compositions and methods provide for the complete removal of synthetic glues or adhesives from a plurality of surfaces through the use of organic solvents and/or amine solvents in combination with surfactants, chelants, acidulants and/or additional bottle wash additives. Beneficially, the compositions and methods are suitable for use at lower temperatures and pH conditions that conventional caustic-based adhesive removal compositions. | 2013-11-14 |
20130303423 | ENZYME STABILIZED DETERGENT COMPOSITIONS - Biodegradable detergent compositions comprising enzymes and 1,3-propanediol are provided. The 1,3-propanediol in the composition is biologically derived and enhances the stability of the enzymes in the composition. The compositions also exhibit a low anthropogenic CO | 2013-11-14 |
20130303424 | DETERGENT COMPOSITION - An automatic dishwashing detergent composition comprising:
| 2013-11-14 |
20130303425 | Liquid Detergent Composition for Improved Shine - A liquid detergent composition having a modified polyethyleneimine polymer and a surfactant to provide improved shine on hard surfaces. | 2013-11-14 |
20130303426 | Liquid Detergent Composition for Improved Shine - A liquid detergent composition having a modified polyethyleneimine polymer and a surfactant to provide improved shine on hard surfaces. | 2013-11-14 |
20130303427 | MICROCAPSULE COMPOSITIONS COMPRISING pH TUNEABLE DI-AMIDO GELLANTS - The invention is directed to microcapsule compositions comprising a pH tuneable di-amido gellant and a surfactant, fluid laundry detergent compositions comprising the microcapsule compositions, and methods for preparing the compositions. | 2013-11-14 |
20130303428 | Laundry Detergent Composition Comprising A Particle Having Hueing Agent and Clay - The present invention relates to a laundry detergent composition comprising a particle comprising hueing agent and clay. The particle can be incorporated into laundry detergent products, such as a laundry detergent powder. The particle exhibits an excellent storage stability profile with very little bleeding of the hueing dye from the particle, exhibits excellent fabric deposition of the hueing dye during a laundering process without causing any spot staining of the fabric, and does not impact the visual appearance of a laundry detergent powder when incorporated therein. | 2013-11-14 |
20130303429 | LAUNDRY DETERGENT COMPOSITION COMPRISING A PARTICLE HAVING HUEING AGENT AND CLAY - A laundry detergent composition having a particle, wherein the particle has: (a) hueing agent, wherein the hueing agent has the following structure: | 2013-11-14 |
20130303430 | ALKOXYLATED ALCOHOLS AND THEIR USE IN FORMULATIONS FOR HARD SURFACE CLEANING - Alkoxylated alcohols and their use in formulations for hard surface cleaning Formulations, comprising at least one compound according to general formula (I) | 2013-11-14 |
20130303431 | VISUALLY PERCEIVABLE IMAGE-FORMING DYE SCAVENGING ARTICLE - The present application relates to a visually perceivable image-forming dye scavenging article capable of absorbing and/or inhibiting transfer of fugitive dyes released during laundering, the article comprising (i) a support substrate with an imprint of an image on at least one surface of the substrate; (ii) at least one dye scavenging compound fixably adhered to the imprinted image; (iii) optionally, a film forming agent; (iv) optionally, a cross-linking agent; (v) optionally, a rheology modifying agent; and (vi) optionally, a catalyst to accelerate the polymerization reaction. Also disclosed is a method of manufacturing the article and use of the same. | 2013-11-14 |
20130303432 | Use Of Specific Compounds For Modifying Odors - The use of certain compounds for masking or decreasing the or one or a plurality of unpleasant olfactory impressions of one or a plurality of substances with an unpleasant odor and/or for enhancing the or one or a plurality of pleasant olfactory impressions of one or a plurality of substances with a pleasant odor and new fragrance mixtures and perfumed products containing such compounds. | 2013-11-14 |
20130303433 | Cyclohexene- And Cyclopropanated Cyclohexene- Derivatives As Fragrances - 1-(3/4-isobutyl-1/6-methylcyclohex-3-enyl)methanols and derivatives thereof having appreciable floral and hesperidic odor notes, their use as fragrance ingredient and perfumed products comprising them. | 2013-11-14 |
20130303434 | HIGH PERFORMANCE FRAGRANCE FORMULATION - A method of formulating a high performance fragrance formulation by selecting an effective amount of fragrance ingredients selected from the group consisting of aroma chemicals and essential oils defined according to the following algorithm: | 2013-11-14 |
20130303435 | Smart Pro-Drugs of Serine Protease Inhibitors - The present invention relates to prodrugs of protease inhibitors, such as inhibitors of the proteosome, DPP IV, FAPα and the like. These“pro-inhibitors” are activated, i.e., cleaved, by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease can be the same (such as pro-inhibitors being referred to as “Target-Activated Smart Protease Inhibitors” or “TASPI”) or different (e.g., “Target-Directed Smart Protease Inhibitors” or “TDSPI”). After activation of the pro-inhibitor, the active inhibitor moiety can self-inactivate by, e.g., intramolecular-cyclization or cis-trans isomerization. | 2013-11-14 |
20130303436 | PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME - Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2′6′-Dmt-Lys-Phe-NH | 2013-11-14 |
20130303437 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS - The disclosure provides a molecular genetic approach of targeted mutagenesis and heterologous expression, coupled with in vitro and in vivo models of bacterial pathogenesis, to demonstrate that the | 2013-11-14 |
20130303438 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION - The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same. | 2013-11-14 |
20130303439 | CHIMERIC PEPTIDES INCLUDING A PENETRATING PEPTIDE AND A BINDING DOMAIN OF PP2A CATALYTIC SUBUNIT TO CASPASE-9 - The invention related to chimeric peptides including a penetrating peptide and a binding domain of PP2A catalytic subunit to caspase-9 which have pro-apoptotic activity. These chimeric peptides may be used for the treatment of hyperproliferative disorders. | 2013-11-14 |
20130303440 | AXMI-192 FAMILY OF PESTICIDAL GENES AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:28-62, or the nucleotide sequence set forth in SEQ ID NO:1-27, as well as variants and fragments thereof. | 2013-11-14 |
20130303441 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS - Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are substrate-competitive inhibitors and have an amino acid sequence designed so as to bind to a defined binding site subunit in GSK-3. | 2013-11-14 |
20130303442 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME - The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use. | 2013-11-14 |
20130303443 | NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR - Peptide analogues of PYY, compositions comprising said analogues, and methods of using said analogues for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for reduction in appetite, reduction in food intake or reduction of calorie intake in a subject, are provided herein. | 2013-11-14 |
20130303444 | CRYSTALLINE FORMS OF THE DI-SODIUM SALT OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID - The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same. | 2013-11-14 |
20130303445 | METHOD FOR IMPROVING THE PHARMACEUTIC PROPERTIES OF MICROPARTICLES COMPRISING DIKETOPIPERAZINE AND AN ACTIVE AGENT - Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery. | 2013-11-14 |
20130303446 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to a pharmaceutical combination comprising the compound of formula I | 2013-11-14 |
20130303447 | METHODS FOR PREVENTING OR TREATING INSULIN RESISTANCE - The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 2013-11-14 |
20130303448 | Therapeutic or Preventive Agent for Diabetes - A collagen peptide mixture containing three or more kinds selected from Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, chemically-modified substances thereof and pharmaceutically acceptable salts thereof, and at least one peptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, Ser-Hyp-Gly, Gly-Pro-Hyp, (Pro-Hyp-Gly) | 2013-11-14 |
20130303449 | SURGICAL APPLICATIONS FOR BMP BINDING PROTEIN - The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired. | 2013-11-14 |
20130303450 | USE OF SOMATOSTATIN ANALOGS IN MENINGIOMA - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma. | 2013-11-14 |
20130303451 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME - A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 2013-11-14 |
20130303452 | PEPTIDE ANALOGS OF ALPHA-MELANOCYTE STIMULATING HORMONE - Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (α-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the α-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R. | 2013-11-14 |
20130303453 | OCTREOTIDE INJECTION - The present invention provides a sterile solution comprising octreotide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in multiple daily doses and further being adapted to provide multiple portions of the said solution, while the reservoir remains sterile. | 2013-11-14 |
20130303454 | LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF - Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus. | 2013-11-14 |
20130303455 | PREDICTION AND PREVENTION OF PREECLAMPSIA - The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing risk of preeclampsia through administration of a pharmaceutical formulation of relaxin to a pregnant woman. | 2013-11-14 |
20130303456 | METHOD OF TREATING ABNORMAL ANGIOGENESIS VIA THE BAI FAMILY OF PROTEINS AND THEIR PROTEIN FRAGMENTS - The present disclosure encompasses the protein BAI1, and two cleavage products thereof, Vstat120 and Vstat40. The disclosure also describes the use of BAI1, and two cleavage products thereof, Vstat120 and Vstat40, as an anti-angiogenic and anti-tumorigenic therapy for gliomas as well as its other types of cancer and conditions involving aberrant angiogenesis. One aspect of the disclosure therefore provides a polypeptide, derived from the protein BAI1, comprising an integrin binding domain and a thrombospondin type 1 repeat. Another aspect of the disclosure provides methods of inhibiting the formation of a tumor sustained or disseminated by angiogenesis, comprising: contacting a developing tumor with one of the polypeptides derived from the protein BAI1 whereupon angiogenesis is inhibited, and thereby inhibiting the formation of the tumor. Another aspect of the disclosure is pharmaceutical compositions comprising a Vstat120 and Vstat40 polypeptide, or variants thereof, an at least one carrier for delivery to an animal or human patient. | 2013-11-14 |
20130303457 | CELL-PROTECTIVE PEPTIDES AND USES THEREOF - A peptide comprising the amino acid sequence, X | 2013-11-14 |
20130303458 | SUBSTANCES AND METHODS FOR THE TREATMENT OF B CELL MEDIATED MULTIPLE SCLEROSIS - The invention relates to the Fcγ receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fcγ receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. | 2013-11-14 |
20130303459 | TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN - The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia. | 2013-11-14 |
20130303460 | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF NEUROECTODERMAL DERIVED TUMORS AND RETINOBLASTOMA - The present invention is directed to compositions and methods for the treatment of retinoblastoma and neuroectodermal derived tumors, such as primitive neuroectodermal tumors (PNET) and neuroblastoma. In particular, the present invention is directed to the use of 4F-benzoyl-TN14003 peptide or analogs or derivatives thereof for treating neuroblastoma and retinoblastoma. | 2013-11-14 |
20130303461 | METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCE - The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences. | 2013-11-14 |
20130303462 | USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME - The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome. | 2013-11-14 |
20130303463 | TREATMENT OF DISEASES - The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration of the diketopiperazine, the prodrug or the pharmaceutically-acceptable salt according to a method of the invention. The diketopiperazines have the formula given in the application. | 2013-11-14 |
20130303464 | STABLE READY-TO-USE CETRORELIX INJECTION - The present invention discloses a stable ready-to-use aqueous pharmaceutical preparation containing Cetrorelix or its pharmaceutically acceptable salt, wherein the preparation does not contain any surfactant. Further, the present invention discloses process for the preparation of said stable ready-to-use aqueous pharmaceutical preparation. | 2013-11-14 |
20130303465 | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors - This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. | 2013-11-14 |
20130303466 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention. | 2013-11-14 |
20130303467 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME - The present invention relates to physical crystal structures of a compound of the formula I: | 2013-11-14 |
20130303468 | VICENIN 2 AND ANALOGUES THEREOF FOR USE AS AN ANTISPASMODIC AND/OR PROKINETIC AGENT - Provided are compositions comprising an active ingredient having antispasmodic and/or prokinetic activity, preferably vicenin 2 or biologically active analogues thereof. | 2013-11-14 |
20130303469 | EXTRACTION METHOD FOR ILEX KUDINGCHA C. J. TSENG LEAVES, TOTAL SAPONINS AND USE THEREOF - The present invention provides an extraction method for the leaves of | 2013-11-14 |
20130303470 | PLANT EXTRACTION METHOD AND COMPOSITIONS - The present invention pertains to methods of extracting cardiac glycosides from cardiac glycoside containing plant material, such as | 2013-11-14 |
20130303471 | NOVEL PYRAZOLE COMPOUNDS - The present invention provides a compound of Formula II: | 2013-11-14 |
20130303472 | SOLID STATE FORMS OF FIDAXOMYCIN AND PROCESSES FOR PREPARATION THEREOF - The present invention provides solid state forms of Fidaxomycin, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising one or more of the solid state forms of Fidaxomycin, and processes for the preparation of the compositions and formulations. The solid state forms of the present invention exhibit advantageous properties such as improved reliability and reproducibility in manufacturing and processing and stability in formulations. | 2013-11-14 |
20130303473 | LIQUID PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A POSTERIOR EYE DISEASE - The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes. | 2013-11-14 |
20130303474 | COMPOSITION FOR ENHANCING IMMUNITY CONTAINING COMPOUNDS REPRESENTED BY CHEMICAL FORMULAS 1-8 OR SOPHORA FLAVESCENS EXTRACT AS ACTIVE INGREDIENT - The present invention relates to a composition for enhancing immunity through inducing the expression of interferon-β comprising a compound represented by Formulas 1 to 8, or | 2013-11-14 |
20130303475 | TOBRAMYCIN FORMULATION - This invention provides a pharmaceutical solution formulation comprising tobramycin, water, sodium chloride and sodium citrate, wherein the formulation has a pH of 4.5-7.0 and an osmolality of 135-200 mOsmol/Kg. | 2013-11-14 |
20130303476 | Aminoglycoside and Fosfomycin Combination for Treatment of Ventilator Associated Pneumonia (VAP) and Ventilator Associated Tracheal (VAT) Bronchitis - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 2013-11-14 |
20130303477 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 2013-11-14 |
20130303478 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 2013-11-14 |
20130303479 | Antiretroviral Cyclonucleoside Compositions and Methods and Articles of Title of Invention Manufacture Therewith - ASPECTS OF EMBODIMENTS RELATE TO methods of treating human immunodeficiency virus (HIV) infection. Further aspects of embodiments also relate to constellations of compositions for treating HIV infection. Still additional aspects of embodiments relate to a many methods of making compositions useful in the treatment of HIV infection. | 2013-11-14 |
20130303480 | SOFT TISSUE AUGMENTATION THREADS AND METHODS OF USE THEREOF - This disclosure relates generally to soft tissue augmentation threads, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, soft tissue augmentation products), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like. | 2013-11-14 |
20130303481 | TREATMENT OF MYELOSUPPRESSION - Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids. | 2013-11-14 |
20130303482 | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors - This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. | 2013-11-14 |
20130303483 | COSMETIC - A cosmetic comprising the following components (A), (B), (C) and (D):
| 2013-11-14 |
20130303484 | Prodrugs of Modulators of ABC Transporters - The present invention relates to prodrugs of modulators of ABC transporters, particularly, CFTR modulators, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-11-14 |
20130303485 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. Although an oral dosage form with enhanced bioavailability with respect to the bisphosphonate compound can be used, the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced. | 2013-11-14 |
20130303486 | Compositions Comprising Zoledronic Acid or Related Compounds for Relieving Pain Associated with Arthritis - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. Although an oral dosage form with enhanced bioavailability with respect to the bisphosphonate compound can be used, the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced. | 2013-11-14 |
20130303487 | Compositions Comprising Zoledronic Acid or Related Compounds for Relieving Inflammatory Pain and Related Conditions - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. Although an oral dosage form with enhanced bioavailability with respect to the bisphosphonate compound can be used, the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced. | 2013-11-14 |
20130303488 | Compositions Comprising Zoledronic Acid or Related Compounds for Treatment of Complex Regional Pain Syndrome - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. Although an oral dosage form with enhanced bioavailability with respect to the bisphosphonate compound can be used, the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced. | 2013-11-14 |
20130303489 | MULTIKINASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER - The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): | 2013-11-14 |
20130303490 | Inhibitors of HIV Infections and uses thereof - The invention relates to compounds which are agonists of at least one receptor selected from S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 receptors, for use in methods for treating HIV infections in humans or animals. | 2013-11-14 |
20130303491 | Antiviral Drugs for Treatement or Prevention of Dengue Infection - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. | 2013-11-14 |
20130303492 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS - Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition. | 2013-11-14 |
20130303493 | Triazole Compounds that Modulate HSP90 Activity - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound. | 2013-11-14 |
20130303494 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2013-11-14 |
20130303495 | EMULSION FORMULATIONS - A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters. | 2013-11-14 |
20130303496 | Method Of Treating Vascular Lesions - The present invention relates to the treatment of vascular lesions using low doses of an mTOR inhibitor together with a low dose of a glucocorticoid on an implantable medical device, wherein the treatment is particularly beneficial when the patient is a diabetic or is suffering from an abnormally long or diffuse lesion. | 2013-11-14 |
20130303497 | DEUTERATED 5-HT1A RECEPTOR AGONISTS - The present invention relates to new deuterated derivatives of serotonin 5-HT1A receptor agonists of formula 1 and in particular to compositions and methods for therapeutic use. | 2013-11-14 |
20130303498 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid - An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. | 2013-11-14 |
20130303499 | GLUCOCORTICOIDS ATTACHED TO NITRATE ESTERS VIA AN AROMATIC LINKER IN POSITION 21 AND THEIR USE IN OPHTHALMOLOGY - The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea. | 2013-11-14 |
20130303500 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA - The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia. | 2013-11-14 |
20130303501 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM - A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition. | 2013-11-14 |
20130303502 | Preparations of Hydrophobic Therapeutic Agents, Methods of Manufacture and Use Thereof - The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma). | 2013-11-14 |
20130303503 | Personal Cleansing Compositions Comprising Zinc Pyrithione - The present invention relates to a personal cleansing composition with an antimicrobial effect. The personal cleansing composition is in the form of a bar soap and contains zinc pyrithione and a soap surfactant. When dispersed in an aqueous solution at 1 wt %, the personal cleansing composition of the present invention is characterized by a pH value ranging that is higher than about 9.6 and lower than about 10.3. The present invention also relates to a process for forming an antimicrobial bar soap as described hereinabove. | 2013-11-14 |
20130303504 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2013-11-14 |